Griffin Asset Management Inc. Sells 19,902 Shares of Pulse Biosciences, Inc. (NASDAQ:PLSE)

Griffin Asset Management Inc. reduced its stake in Pulse Biosciences, Inc. (NASDAQ:PLSE) by 7.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 237,547 shares of the company’s stock after selling 19,902 shares during the period. Griffin Asset Management Inc.’s holdings in Pulse Biosciences were worth $4,136,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. SG Americas Securities LLC acquired a new position in Pulse Biosciences in the 4th quarter valued at about $193,000. Franklin Resources Inc. acquired a new stake in shares of Pulse Biosciences during the third quarter worth $378,000. Creative Planning lifted its holdings in shares of Pulse Biosciences by 113.9% during the third quarter. Creative Planning now owns 21,910 shares of the company’s stock worth $384,000 after buying an additional 11,667 shares in the last quarter. Barclays PLC boosted its position in shares of Pulse Biosciences by 361.4% in the third quarter. Barclays PLC now owns 30,306 shares of the company’s stock valued at $530,000 after acquiring an additional 23,738 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new position in shares of Pulse Biosciences in the third quarter valued at about $588,000. 76.95% of the stock is owned by institutional investors.

Pulse Biosciences Price Performance

PLSE opened at $18.66 on Tuesday. Pulse Biosciences, Inc. has a 52-week low of $6.59 and a 52-week high of $22.69. The business’s fifty day moving average is $18.38 and its 200-day moving average is $17.72.

Pulse Biosciences (NASDAQ:PLSE) last released its earnings results on Wednesday, October 30th. The company reported ($0.21) earnings per share for the quarter. During the same period in the previous year, the company posted ($0.19) earnings per share.

Insider Activity at Pulse Biosciences

In other news, Director Robert W. Duggan purchased 55,256 shares of the company’s stock in a transaction dated Friday, December 13th. The stock was bought at an average cost of $17.18 per share, for a total transaction of $949,298.08. Following the purchase, the director now owns 42,328,717 shares of the company’s stock, valued at approximately $727,207,358.06. The trade was a 0.13 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Burke Thomas Barrett sold 50,000 shares of the company’s stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $17.42, for a total value of $871,000.00. Following the completion of the transaction, the chief executive officer now directly owns 63,172 shares of the company’s stock, valued at approximately $1,100,456.24. The trade was a 44.18 % decrease in their position. The disclosure for this sale can be found here. 71.50% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Separately, StockNews.com raised shares of Pulse Biosciences to a “sell” rating in a report on Thursday, January 2nd.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.